Because metastatic solid organ tumors are often incurable with standard approaches, other strategies such as inducing immune responses against the tumor are being explored. The purpose of this study is to evaluate the safety and feasibility of one such form of immunotherapy, vaccinations with potent immune stimulating cells called dendritic cells (DC) loaded with a peptide fragment of a tumor- associated protein, carcinoembryonic antigen (CEA) for patients with metastatic CEA expressing malignancies such as gastrointestinal, lung, and breast cancers. Patients are screened to assure that they are immune type HLA-A2, have a tumor that expresses CEA, and have advanced or metastatic disease that has failed conventional therapy. Eligible patients are leukapheresed, their peripheral blood mononuclear cells are cultured with GM-CSF and IL-4 to produce DC, and the DC are mixed with CEA peptide. Patients are assigned to the appropriate dose levels and receive intravenous and intradermal injections of the dendritic cells on day one of weeks 0, 2, 4, and 6. A repeat leukapheresis is performed at the end of the immunizations to determine the immune response induced against CEA. The goal was to enroll 18 evaluable patients, defined as those who received all immunizations and underwent the final leukpaheresis. We have completed enrollment and treatment of the patients on this study and are now following them for toxicities, immune responses, and progression-free survival. Twenty one patients were enrolled and 15 were evaluable (the remainder did not receive all the immunizations or undergo the follow-up leukpaheresis). There were no toxicities directly referable to the treatments. One patient had a minor response and one stable disease. The immunologic response data is being analyzed presently. This study is significant in that it demonstrates the safety and feasibility of this approach and provides the groundwork for phase II studies of the immunologic efficacy of these vaccines. We plan to focus on settings of minimal residual disease for the phase II studies, including after resection of localized pancreatic cancer.
| Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201 |
| Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445 |
| Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247 |
| James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4 |
| Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628 |
| Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417 |
| Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213 |
| Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17 |
| Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79 |
| Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32 |
Showing the most recent 10 out of 128 publications
